Are you Dr. Lee?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Drive, Bldg10
Room12n226
Rockville, MD 20814Phone+1 301-443-7735Fax+1 212-932-5258
Summary
- Dr. Jung-Min Lee, MD is an oncologist in Rockville, Maryland. She is currently licensed to practice medicine in New York.
Certifications & Licensure
NY State Medical License 2007 - 2026
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsDistinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer.Jayakumar R Nair, Tzu-Ting Huang, Anu Sunkara, Margaret R Pruitt, Kristen R Ibanez
Iscience. 2024-12-20 - 2 citationsCediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-...Jung-Min Lee, Mark F Brady, Austin Miller, Richard G Moore, Helen MacKay
Journal of Clinical Oncology. 2024-12-20 - Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge.Chi-Ting Shih, Tzu-Ting Huang, Jayakumar R Nair, Kristen R Ibanez, Jung-Min Lee
Cells. 2024-11-07
Press Mentions
Pembrolizumab Improves Survival in Advanced Triple-Negative Breast CancerAugust 9th, 2022- The Power of Shared Purpose: Transforming Gynecologic Cancer CareMarch 26th, 2024
Grant Support
- Leveraging DNA damage repair pathways as therapeutic targets in womens cancersDIVISION OF BASIC SCIENCES - NCIPresent
- Leveraging DNA damage repair pathways as therapeutic targets in womens cancersDIVISION OF BASIC SCIENCES - NCIPresent
